145 related articles for article (PubMed ID: 14639615)
1. Serum enterolactone concentration is not associated with breast cancer risk in a nested case-control study.
Kilkkinen A; Virtamo J; Vartiainen E; Sankila R; Virtanen MJ; Adlercreutz H; Pietinen P
Int J Cancer; 2004 Jan; 108(2):277-80. PubMed ID: 14639615
[TBL] [Abstract][Full Text] [Related]
2. Serum enterolactone concentration is not associated with prostate cancer risk in a nested case-control study.
Kilkkinen A; Virtamo J; Virtanen MJ; Adlercreutz H; Albanes D; Pietinen P
Cancer Epidemiol Biomarkers Prev; 2003 Nov; 12(11 Pt 1):1209-12. PubMed ID: 14652283
[TBL] [Abstract][Full Text] [Related]
3. Serum enterolactone and risk of breast cancer: a case-control study in eastern Finland.
Pietinen P; Stumpf K; Männistö S; Kataja V; Uusitupa M; Adlercreutz H
Cancer Epidemiol Biomarkers Prev; 2001 Apr; 10(4):339-44. PubMed ID: 11319174
[TBL] [Abstract][Full Text] [Related]
4. Circulating enterolactone and prostate cancer risk: a Nordic nested case-control study.
Stattin P; Adlercreutz H; Tenkanen L; Jellum E; Lumme S; Hallmans G; Harvei S; Teppo L; Stumpf K; Luostarinen T; Lehtinen M; Dillner J; Hakama M
Int J Cancer; 2002 May; 99(1):124-9. PubMed ID: 11948503
[TBL] [Abstract][Full Text] [Related]
5. Risk of acute coronary events according to serum concentrations of enterolactone: a prospective population-based case-control study.
Vanharanta M; Voutilainen S; Lakka TA; van der Lee M; Adlercreutz H; Salonen JT
Lancet; 1999 Dec 18-25; 354(9196):2112-5. PubMed ID: 10609816
[TBL] [Abstract][Full Text] [Related]
6. Serum enterolactone and postmenopausal breast cancer risk by estrogen, progesterone and herceptin 2 receptor status.
Zaineddin AK; Vrieling A; Buck K; Becker S; Linseisen J; Flesch-Janys D; Kaaks R; Chang-Claude J
Int J Cancer; 2012 Mar; 130(6):1401-10. PubMed ID: 21544804
[TBL] [Abstract][Full Text] [Related]
7. Circulating enterolactone and risk of breast cancer: a prospective study in New York.
Zeleniuch-Jacquotte A; Adlercreutz H; Shore RE; Koenig KL; Kato I; Arslan AA; Toniolo P
Br J Cancer; 2004 Jul; 91(1):99-105. PubMed ID: 15226762
[TBL] [Abstract][Full Text] [Related]
8. Plasma enterolactone and genistein and the risk of premenopausal breast cancer.
Piller R; Chang-Claude J; Linseisen J
Eur J Cancer Prev; 2006 Jun; 15(3):225-32. PubMed ID: 16679865
[TBL] [Abstract][Full Text] [Related]
9. Plasma enterolactone and breast cancer incidence by estrogen receptor status.
Olsen A; Knudsen KE; Thomsen BL; Loft S; Stripp C; Overvad K; Møller S; Tjønneland A
Cancer Epidemiol Biomarkers Prev; 2004 Dec; 13(12):2084-9. PubMed ID: 15598765
[TBL] [Abstract][Full Text] [Related]
10. Determinants of serum enterolactone concentration.
Kilkkinen A; Stumpf K; Pietinen P; Valsta LM; Tapanainen H; Adlercreutz H
Am J Clin Nutr; 2001 Jun; 73(6):1094-100. PubMed ID: 11382665
[TBL] [Abstract][Full Text] [Related]
11. Serum enterolactone concentration and the risk of coronary heart disease in a case-cohort study of Finnish male smokers.
Kilkkinen A; Erlund I; Virtanen MJ; Alfthan G; Ariniemi K; Virtamo J
Am J Epidemiol; 2006 Apr; 163(8):687-93. PubMed ID: 16510545
[TBL] [Abstract][Full Text] [Related]
12. Serum enterolactone levels and mortality outcome in women with early breast cancer: a retrospective cohort study.
Guglielmini P; Rubagotti A; Boccardo F
Breast Cancer Res Treat; 2012 Apr; 132(2):661-8. PubMed ID: 22094938
[TBL] [Abstract][Full Text] [Related]
13. Plasma enterolactone and breast cancer risk in the Nurses' Health Study II.
Xie J; Tworoger SS; Franke AA; Terry KL; Rice MS; Rosner BA; Willett WC; Hankinson SE; Eliassen AH
Breast Cancer Res Treat; 2013 Jun; 139(3):801-9. PubMed ID: 23760859
[TBL] [Abstract][Full Text] [Related]
14. Circulating enterolactone and risk of endometrial cancer.
Zeleniuch-Jacquotte A; Lundin E; Micheli A; Koenig KL; Lenner P; Muti P; Shore RE; Johansson I; Krogh V; Lukanova A; Stattin P; Afanasyeva Y; Rinaldi S; Arslan AA; Kaaks R; Berrino F; Hallmans G; Toniolo P; Adlercreutz H
Int J Cancer; 2006 Nov; 119(10):2376-81. PubMed ID: 16929490
[TBL] [Abstract][Full Text] [Related]
15. An incident case-referent study on plasma enterolactone and breast cancer risk.
Hultén K; Winkvist A; Lenner P; Johansson R; Adlercreutz H; Hallmans G
Eur J Nutr; 2002 Aug; 41(4):168-76. PubMed ID: 12242585
[TBL] [Abstract][Full Text] [Related]
16. Serum enterolactone and prognosis of postmenopausal breast cancer.
Buck K; Vrieling A; Zaineddin AK; Becker S; Hüsing A; Kaaks R; Linseisen J; Flesch-Janys D; Chang-Claude J
J Clin Oncol; 2011 Oct; 29(28):3730-8. PubMed ID: 21900115
[TBL] [Abstract][Full Text] [Related]
17. Prospective study of plasma enterolactone and prostate cancer risk (Sweden).
Stattin P; Bylund A; Biessy C; Kaaks R; Hallmans G; Adlercreutz H
Cancer Causes Control; 2004 Dec; 15(10):1095-102. PubMed ID: 15801493
[TBL] [Abstract][Full Text] [Related]
18. Enterolactone is differently associated with estrogen receptor beta-negative and -positive breast cancer in a Swedish nested case-control study.
Sonestedt E; Borgquist S; Ericson U; Gullberg B; Olsson H; Adlercreutz H; Landberg G; Wirfält E
Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3241-51. PubMed ID: 18990767
[TBL] [Abstract][Full Text] [Related]
19. Use of oral antimicrobials decreases serum enterolactone concentration.
Kilkkinen A; Pietinen P; Klaukka T; Virtamo J; Korhonen P; Adlercreutz H
Am J Epidemiol; 2002 Mar; 155(5):472-7. PubMed ID: 11867359
[TBL] [Abstract][Full Text] [Related]
20. Enterolactone concentrations and prognosis after postmenopausal breast cancer: assessment of effect modification and meta-analysis.
Seibold P; Vrieling A; Johnson TS; Buck K; Behrens S; Kaaks R; Linseisen J; Obi N; Heinz J; Flesch-Janys D; Chang-Claude J
Int J Cancer; 2014 Aug; 135(4):923-33. PubMed ID: 24436155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
